key: cord-1033288-dtkg9lbz
authors: Aryanian, Zeinab; Balighi, Kamran; Hatami, Parvaneh; Goodarzi, Azadeh; Mohandesi, Nessa Aghazadeh; Afshar, Zeinab Mohseni
title: SARS‐CoV‐2 vaccination and practical points in psoriasis patients: A narrative review
date: 2022-03-22
journal: Dermatol Ther
DOI: 10.1111/dth.15430
sha: b9f722ef420edb3ff332f6720c922ef7ac52c8fa
doc_id: 1033288
cord_uid: dtkg9lbz

SARS‐CoV2 vaccines were approved without long‐term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS‐CoV‐2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine‐triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS‐CoV‐2 vaccines. It is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS‐CoV‐2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease.

The coronavirus disease 2019 (COVID-19) has led to a great rate of morbidity and mortality since its emergence. COVID-19 vaccination has proven to be highly safe and effective in clinical trials and real world, however, some unique challenges have risen especially in individuals with underlying diseases who are at as higher risk of complications. 1 Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been followed by several local and systemic cutaneous adverse events. Among them, local injection site reactions, urticarial eruptions and maculopapular rash have occurred with the highest frequency, most of which have been self-limited. [2] [3] [4] [5] [6] [7] New-onset and exacerbation of some dermatological disorders, including lichen planus and psoriasis, have been reported following COVID-19 vaccination. 8 Psoriasis is a common chronic inflammatory dermatosis which can affect the skin, nails, and the axial and peripheral joints. 9,10 Psoriasis patients on immunosuppressive medications are at increased risks of infectious complication potentially including more severe forms of SARS-CoV-2 infection. 11, 12 Vaccination, along with social distancing and utilization of masks, can be an excellent strategy to decreased the risk of acquisition and complications associated with COVID-19 in psoriasis patients, particularly those on immunomodulatory/ immunosuppressive therapy. 13, 14 Immunosuppressive medications, however, are likely to affect the vaccine response and interfere with antibody production. 15 Therefore, planned timing of vaccination, as much as possible may be crucial in some patients. Furthermore, studies suggest that individuals with inflammatory conditions such as psoriasis may have vaccine hesitancy due to concerns for disease exacerbation following vaccination. 8, 16 Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges.

Psoriasis, per se, is not a state of immunosuppression, but it causes a milieu of systemic inflammation in the body. 17 Tissue angiotensin converting enzyme (ACE) activity, which is the main component for SARS-CoV-2 spike protein binding, is higher in psoriasis patients, which, in theory, could lead to more severe COVID-19 infections. 18 Moreover, immunosuppressant agents used for psoriasis precipitate the host to get an infection. 19 Agents such as interleukin (IL)-17 inhibitors, which are the cornerstone of psoriasis treatment, can impair the mucosal immunity, thereby increase the risk of lower respiratory tract infections. 20 Anti-tumor necrosis factor (anti-TNF) agents as well as conventional immunosuppressive agents such as methotrexate and cyclosporine which are sometimes utilized for psoriasis management would also increase the risk of pulmonary infections, including SARS-Cov-2 ones. [21] [22] [23] On the other hand, retinoids such as acitretin, due to their anti-inflammatory characteristics, may even have antiviral effects. 24 These problems had led the dermatologist to cease or reduce the dosage of certain medications in psoriasis patients. 25 1.2 | The impact of SARS-CoV-2 infection and medications used for its management on the course of psoriasis Considering the hyper-inflammatory state and cytokine release along with ACE over-activity occurring in the settings of SARS-CoV-2 infection, psoriasis can be induced or exacerbated by COVID-19. 26, 27 Moreover, hydroxychloroquine (HCQ), which was widely utilized in the early days of COVID-19 pandemic, can be trigger psoriasis onset in predisposed individuals or its exacerbation. 28 The pathophysiologic mechanism might be blockade of epidermal transglutaminase activity by HCQ, which results in epidermal barrier break and subsequently psoriasis induction or flare-up. The increased production of IL-17 by HCQ can lead to keratinocyte overgrowth. 29, 30 Azithromycin, which was also commonly used in the beginning of the COVID-19 outbreak, may potentially improve psoriatic lesions by its immunomodulatory effect on keratinocytes and epidermal Langerhans cells. 31 

Since some individuals with psoriasis are potentially at increased risk of severe COVID-19 due to immunosuppressant agent usage, vaccination against COVID-19 seems to be necessary for this population. 32 However, there are several challenges for vaccinating these patients.

In general, several factors, such as genetic, stress, trauma, drugs and infections, are involved in the introduction or exacerbation of skin disorders, including psoriasis. 33 Reviewing the literature reveals, several cases of de novo psoriasis or disease flare up following SARS-CoV-2 infection. [34] [35] [36] Vaccination has also been reported as a triggering factor for the evolution or exacerbation of psoriasis. The vaccine-induced psoriasis is so prevalent that the term "psoriasis vaccinalis" has been suggested for vaccine-induced new-onset psoriasis. 37 New-onset psoriasis or flare-up has been reported following several vaccines, including yellow fever, tetanus-diphteria, BCG, pneumococcal polysaccharide, and influenza vaccines. 38 The underlying mechanism could be the immunologic reaction to vaccine adjuvants and immune system dysregulation due to viral component, which may lead to epidermal changes and induction or exacerbation of certain cutaneous disorders such as psoriasis. 38, 56 It is believed that induction of neutralizing antibodies and T-cell responses by vaccines can lead to increased TNF-α and interferon (IFN)-γ production. 57 In addition, plasmacytoid and dermal myeloid dendritic cells might be activated with vaccination. All of these conditions can be a trigger for psoriasis cascade. 57, 58 Moreover, vaccines might induce IL-6 production, which is the trigger for T helper (Th) 17 cells to produce IL-22, which itself stimulates keratinocyte proliferation, lead to epidermal changes, and consequently psoriasis induction or exacerbation. 56, 59 However, it is believed that mRNA vaccines, due to their modifying effect on toll-like receptors, can potentially decrease the risk of exacerbation in autoimmune diseases like psoriasis. 60 Nonetheless, this hypothesis should be proved since several psoriasis flares have been reported following receiving SARS-CoV-2 mRNA vaccines. 32, 61 It is also important to know that psoriasis patients on Apremilast, which is a phosphodiesterase vaccines, because vaccine-induced psoriasis, is rare, short-lived, has a favorable prognosis and responds well to standard treatments. 66, 67 Moreover, psoriasis patients are at increased risk of severe SARS-CoV-2 infection due to the inflammatory nature of this dermatological disorder and also the immunosuppressive medications they use. 27 Therefore, authorities recommend COVID-19 vaccination in all psoriasis patients without confirmed history of allergy to vaccine or any of its components, particularly individuals on any kind of immunosuppressive treatment. 68 However, it should be kept in mind not to administer attenuated live vaccines in those individual on immunomodulatory/immunosuppressive therapy. 69 In these conditions, nonlive vaccines should be considered. Fortunately, none of the currently used SARS-CoV-2 vaccine platforms are live vaccines. Therefore, all psoriasis patients without a history of vaccine allergy or any contraindications, should receive SARS-CoV-2 vaccines as soon as possible. 70 

The immunosuppressed states, such as those induced by medications, can affect the ability of an individual to mount an effective and longstanding humoral, cellular and innate immunity to vaccines. 71 It seems that vaccination is well-tolerated in patients with autoimmune disorders like psoriasis, even though the vaccine-induced immunity might be diminished in those individuals on immunosuppressive agents, namely methotrexate or CD20-targeted agents. 72, 73 However, real world data suggest that even this sub-optimal reduced response can be effective enough to prevent severe forms of SARS-CoV-2 infection.

The most prevalent therapeutics used for psoriasis management include methotrexate, and biologics which target the cytokines such as TNF and ILs. 74 Methotrexate, which is an antimetabolite agent and used in several autoimmune dermatoses including psoriasis, had been showed to impair antibody responses to certain vaccines such as influenza and pneumococcal vaccines. 75, 76 Studies on serologic response to COVID-19 vaccines showed lower seroconversion rates in vaccinated psoriasis patients who were on methotrexate, compared with healthy individuals. Patients on methotrexate achieve the lowest antibody response after vaccination. 75 It appears that methotrexate dampens the humoral immune response, however, the cellular immune response may be relatively intact. Thus, despite the diminished antibody levels, a relatively favorable vaccine response is expected. 77 Biologic agents are other therapeutic regimens approved and commonly utilized for psoriasis patients. This class include anti-TNF-α, and anti-ILs including etanercept, infliximab, and secukinumab. 78 The impact of biologic agents on vaccine immunogenicity are more controversial; some studies acknowledge that targeted biologics, especially anti TNF agents, do not impair antibody response to vaccines and psoriasis patients receiving these agents show normal immunogenicity against SARS-CoV-2 vaccination. 79 For example, secukinumab, which is an IL-17A inhibitor, was shown to have no negative effect on vaccine-induced immunity. 80 Despite all the aforementioned challenges in individuals on immunosuppressant agents, the degree of seroconversion alone does not represent vaccine immunogenicity, since vaccine-induced cellular immunity seems to have a more important role, compared with humoral immunity for achieving protection against respiratory viruses such as influenza and SARS-CoV-2. 81, 82 It has been demonstrated that despite the decreased vaccine-induced humoral immune responses in patients receiving B-call depleting agents, T-cell responses are still intact and the mere cellular responses following vaccination may suffice for protection against SARS-CoV-2. 83 Moreover, supposed that COVID-19 vaccines responses are diminished in psoriasis patients on immunosuppressive agents, it is still unclear whether this leads to increased rate of breakthrough SARS-CoV-2 infections. 84 In addition, vaccine immunogenicity in those patients undergoing immunomodulatory agents varies for different SARS-CoV-2 variants. This highlights the need to receive vaccine booster doses. 85 

Due to the potential for reduced vaccine immune response in patients receiving immunosuppressive therapy, vaccination status should be assessed prior to initiating these therapeutic regimens. 86 Guidelines recommend patients on immunosuppressive therapy to receive live vaccines either 2-4 weeks before starting therapy or 1-3 months after stopping or ending therapy. In contrast, non-live vaccines are allowed concomitantly to immunosuppressive therapy. 14 However, different guidelines have various opinions. In general, SARS-CoV-2 vaccination should be ideally completed at least 2 weeks prior to starting immunosuppressive agents. As COVID-19 vaccines doses are administered at least 4 weeks apart, the decision to hold psoriasis treatment until vaccination completion can have adverse effects on the course of psoriasis, leading to recurrences. 87 Therefore, the risk-benefit should be weighed.

Psoriasis patients are allowed to continue certain immunosuppressive medications, such as biologics during COVID-19 vaccination.

These agents are considered safe and noninterfering with vaccineinduced responses and their dosage does not need to be modified before vaccination. Hence, they can safely be administered concomitant with inactive vaccines, unless used along with methotrexate. 88 Conversely, some authorities recommend psoriasis patients to discontinue treatment with methotrexate during vaccination, due to the diminished antibody response, while some believe it should be stopped 2 weeks before and 2-4 weeks after vaccination. 89 However, due to the risk of exacerbation, some authorities recommend that this agent should be suspended only for 1 week after each vaccine dose. 90 Cyclosporine, a calcineurin inhibitor, despite having similar modifying effect on vaccine response, does not need to be stopped around vaccination time, since it has a relatively short half-life. 91 Mycophenolate mofetil (MMF), it has been shown that temporary holding MMF for at least 1 week helps immune response to COVID vaccination. 92 Azathioprine has a more favorable profile than MMF and cyclosporine in affecting humoral vaccine response, therefore, its continuation seems to be harmless concomitantly with vaccination. 93, 94 Apremilast, which is a selective PDE-4 inhibitor and is widely used for psoriasis, seems to have little adverse effect on vaccine-induced immune response due to its immunomodulatory properties. Therefore, it can probably be used before, during and after the vaccination program. 95 The issue may be somewhat different for timing of treatment with monoclonal antibodies such as rituximab which have seldom been used to treat psoriasis, compared to other dermatoses. [96] [97] [98] [99] It is advised to give space between the last rituximab infusion and vaccination, in order for the immune system to reconstitute B cells and achieve higher seroconversion. If patients are not at risk of organ damage or disease relapse, it is better to delay rituximab administration until completion of COVID-19 vaccination. 99 Some guidelines even recommend to postpone vaccination to at least 6 months after the last rituximab infusion. 100 Nonetheless, every patient should be decided individually based on the risk-benefit ratio.

In brief, for achieving the optimal vaccine response, it is recommended that new immunosuppressive/immunomodulatory therapies be initiated at least 1 week after the second SARS-CoV-2 vaccine dose, if possible. In addition, in severe and active forms of psoriasis, it is better to delay vaccination until stabilization of the disease.

Another important point of view is the fact that although vaccine-induced immune responses are attenuated in psoriasis patients receiving immunosuppressive agents, repeating vaccine doses can further increase T-cell responses following vaccination. Therefore, booster doses seems to be beneficial in these patients. 73 However, booster doses might not be given priority in patients under treatment with anti TNF agents due to reaching to an acceptable level of postvaccine immunity compared to those receiving other immunosuppressant agents. 101 

The authors declare no potential conflict of interest.

All authors contributed to the preparation of data and finalization of this article.

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0002-3531-2907

COVID-19 vaccines: challenges and solutions

COVID-19 vaccine-related new-onset lichen planus

Cutaneous manifestations of COVID-19 in children: practical points for clinicians

The first reported case of delayed-type hypersensitivity reaction to non-hyaluronic acid polycaprolactone dermal filler following COVID-19 vaccination: a case report and a review of the literature

Mucocutaneous adverse effects following COVID-19 vaccination: a comprehensive review of the literature with a presentation of some cases from Iran

Serious health threat of mucormycosis during the ongoing COVID-19 pandemic: what dermatologists need to know in this regards. International Journal of Dermatology

A case of atypical disseminated herpes zoster in a patient with COVID-19; a diagnostic challenge in COVID era

New onset and exacerbation of psoriasis after COVID-19 vaccination

Psoriasis and increased prevalence of hypertension and diabetes mellitus

Echocardiographic and electrocardiographic assessments in patients with psoriasis

Dermatological manifestations associated with COVID-19: a comprehensive review of the current knowledge

Severe COVID-19 outcomes in patients with psoriasis

Vaccinations in patients receiving systemic drugs for skin disorders: what can we learn for SARS-Cov-2 vaccination strategies? Drugs R&D

Immune response to vaccination in patients with psoriasis treated with systemic therapies

Psoriasis and COVID-19: a narrative review with treatment considerations

COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision

Pathogenesis and clinical features of psoriasis. The Lancet

Serum and tissue angiotensin converting enzyme in patients with psoriasis

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in psoriasis patients-a metaestimate of pivotal phase 3 trials relevant to decision-making during the COVID-19 pandemic

The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-a meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic

Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

Retinoic acid analogues inhibit human herpesvirus 8 replication

Dermatologists' attitude towards psoriasis treatment during the COVID-19 pandemic

Covid-19 and exacerbation of psoriasis

Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)?

Caution and clarity required in the use of chloroquine for COVID-19

The in vitro effect of hydroxychloroquine on skin morphology in psoriasis

Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells

Long-term oral azithromycin in chronic plaque psoriasis: a controlled trial

Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases

Psoriasis risk factors and triggers

A challenging case of psoriasis flare-up after COVID-19 infection

Guttate psoriasis secondary to COVID-19

Pustular psoriasis flare-up in a patient with COVID-19

Widespread psoriasis flare following influenza vaccination

National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines

Impact of yellow fever vaccine on patients with psoriasis: preliminary results

Guttate psoriasis-like lesions following BCG vaccination

Psoriasis triggered by tetanus-diphtheria vaccination

Erythrodermic pustular psoriasis triggered by subcutaneous flu vaccine

Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine

New onset guttate psoriasis following pandemic H1N1 influenza vaccination

Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center

Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre

Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine

New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report

Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine

De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine

Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine

Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine

report of two cases

Possible triggering effect of influenza vaccination on psoriasis

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Interferon-α and viral triggers promote functional maturation of human monocyte-derived dendritic cells

Psoriatic skin lesions induced by BCG vaccination

SARS-CoV-2 vaccines and biological treatments: dermatological perspectives

Psoriasis flare up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine

COVID-19 vaccine does not trigger psoriasis flares in psoriatic patients treated with apremilast

Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments

Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies

COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers

Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know

New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin?

Vaccines against SARS-CoV-2 in psoriasis patients on immunosuppressive therapy: implications of vaccination nationwide campaign on clinical practice in Italy

Coronavirus vaccination in patients with Psoriasis vulgaris under immunosuppressive therapy

Safety and impact of anti-COVID-19 vaccines in psoriatic patients treated with biologics: a real life experience

Immunological considerations for COVID-19 vaccine strategies

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokinetreated patients with immune-mediated inflammatory diseases

Infliximab is associated with attenuated immunogenicity to BNT162b2 and

SARS-CoV-2 vaccines in patients with IBD

Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR)

Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexatetreated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors

Influenza vaccination recommendations during use of select immunosuppressants for psoriasis

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Safety of biologics in psoriasis

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial

Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies-executive summary

Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults

Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 2

Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis

Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series

Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients

Antibody response to influenza immunization in kidney transplant recipients receiving either azathioprine or mycophenolate: a controlled trial

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study

Multiple cycles of rituximab therapy for pemphigus: a group of patients with difficultto-treat disease or a consequence of late rituximab initiation?

A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of pemphigus: special focus on COVID-19 pandemic concerns

COVID vaccination in patients under treatment with rituximab: a presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study

Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: a critical appraisal of recent Food and Drug Administration and advisory committee on immunization practices recommendations

SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review